

A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas.

Sub-category: [Translational research](#)

Category: Pancreas, Small Bowel, and Hepatobiliary Tract

Meeting: [2007 Gastrointestinal Cancers Symposium](#)

Abstract No: 106

Author(s): D. Laheru, C. Yeo, B. Biedrzycki, S. Sell, E. Lutz, B. Onners, I. Tartakovsky, R. Hruban, S. Piantadosi, E. Jaffee

Abstract: **Introduction:** Pancreatic cancer remains the fourth leading cause of cancer related deaths in the US. Surgical resection provides the only possibility of cure. Five-year survival remains approximately 15% to 20% with 1- and 2-year survival of 63% and 42% respectively. A standard adjuvant treatment approach for patients with resected disease has not yet been determined. We have developed an irradiated GM-CSF transfected allogeneic whole cell line pancreas adenocarcinoma immunotherapy and previously reported a follow-up 60 patient study in this same population using the highest bioactive immunotherapy dose identified in the initial phase I study. **Methods:** Single institution phase II study of 60 patients with resected pancreatic adenocarcinoma administered a total of five immunotherapy treatments using two pancreatic cancer cell lines each delivering 2.5×10^6 cells ID. Immunotherapy treatment one was administered 8 to 10 weeks following surgical resection. Patients subsequently were treated with 5-FU/Ci based chemotherapy integrated with radiotherapy. Patients who were disease-free 1 month after completion of chemoradiotherapy received immunotherapy treatment 2-4, each 1 month apart. A fifth and final booster immunotherapy treatment was administered 6 months after vaccine 4. **Results:** Median follow-up for these patients was approximately 32 months. 1) The administration of a GM-CSF allogeneic pancreas cancer vaccine is safe and well tolerated. Treatment related side effects included transient vaccine injection site reactions. 2) At this early analysis, the 1- and 2-year survival are 88% and 76% respectively. While the data is only preliminary, this study compares very favorably with the available published data. 3) Follow-up survival data with median follow-up approaching 3 years and a matched cohort analysis comparing patients enrolled on this adjuvant vaccine study to the Johns Hopkins Surgery database will be presented at this meeting.

Associated Presentation(s):

1. **A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas**

Meeting: [2007 Gastrointestinal Cancers Symposium](#)

Presenter: Daniel Laheru, MD

Session: [General Session III: Translational Research](#) (General Session)



2. **A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas**

No presentation available

Meeting: [2007 Gastrointestinal Cancers Symposium](#)

Presenter: Daniel Laheru, MD

Session: [General Poster Session D](#) (Poster Presentation)

Other Abstracts in this Sub-Category


1. **Impact of NAT1 polymorphism on survival of pancreatic cancer.**
Meeting: [2007 Gastrointestinal Cancers Symposium](#) Abstract No: 107 First Author: [A. K. Nook](#)
Category: Pancreas, Small Bowel, and Hepatobiliary Tract - [Translational research](#)
2. **Radiosensitization of human pancreatic cancer through protein kinase C β (PKC β)-mediated suppression of the GSK3 β /catenin Axis.**
Meeting: [2007 Gastrointestinal Cancers Symposium](#) Abstract No: 203 First Author: [A. Spalding](#)
Category: Pancreas, Small Bowel, and Hepatobiliary Tract - [Translational research](#)
3. **Targeting transforming growth factor β (TGF β): type I receptor (T β R) kinase activity: A therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC).**
Meeting: [2007 Gastrointestinal Cancers Symposium](#) Abstract No: 204 First Author: [D. Melis](#)
Category: Pancreas, Small Bowel, and Hepatobiliary Tract - [Translational research](#)

More...

Abstracts by D. Laheru

1. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas.
Meeting: [2007 Gastrointestinal Cancers Symposium](#), Abstract No: 106 First Author: [D. Laheru](#)
Category: Pancreas, Small Bowel, and Hepatobiliary Tract - [Translational research](#)
2. Adjuvant chemoradiation therapy after pancreaticoduodenectomy for intraductal papillary mucinous neoplasm of the pancreas with associated invasive carcinoma.
Meeting: [2007 Gastrointestinal Cancers Symposium](#), Abstract No: 178 First Author: [M. J. Swartz](#)
Category: Pancreas, Small Bowel, and Hepatobiliary Tract - [Multidisciplinary Treatment](#)
3. A multicenter phase 2 consortium (P2C) study of triplaine in patients (pts) with advanced adenocarcinoma of the pancreas.
Meeting: [2006 ASCO Annual Meeting](#), Abstract No: 14118 First Author: [D. L. Grotteltschun](#)
Category: Gastrointestinal (Noncolorectal) Cancer - [Pancreatic Cancer](#)
More...

Presentations by D. Laheru

1. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas
Meeting: [2007 Gastrointestinal Cancers Symposium](#)
Presenter: [Daniel Laheru, MD](#)
Session: [General Session III: Translational Research](#) (General Session)

2. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas
No presentation available
Meeting: [2007 Gastrointestinal Cancers Symposium](#)
Presenter: [Daniel Laheru, MD](#)
Session: [General Poster Session D](#) (Poster Presentation)
More...

Journal of Clinical Oncology Articles by D. Laheru

1. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
J Clin Oncol, United States
Vol 18, No 1 (1/3/2001): pp. 145-56
More...

PubMed Articles by D Laheru



1. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Clin Cancer Res, United States
Vol 12, No 8 (4/28/2006): pp. 2492-7
PMID: 16638357 [PubMed - in process]
2. Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of dietary supplements.
J Altern Complement Med, United States
Vol 11, No 6 (11/02/2005): pp. 1039-46
PMID: 16396566 [PubMed - in process]
3. Pancreatoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for Periapillary Adenocarcinoma-Part 3: Update on 5-Year Survival.
J Gastrointest Surg,
Vol 9, No 9 (12/8/2005): pp. 1191-1206
PMID: 16332474 [PubMed - in process]

More...

